Nexcella registers Phase 3 NEXICART-3 trial of CAR-T NXC-201 in AL amyloidosis
Nexcella Inc. listed a new Phase 3 study comparing its CAR-T therapy NXC-201 with daratumumab plus CyBorD in newly diagnosed AL amyloidosis.
Nexcella Inc. posted one new trial registration on ClinicalTrials.gov.
- "NEXICART-3" (NCT07709715) is a Phase 3, randomized study evaluating the efficacy and safety of NXC-201 compared with Dara-CyBorD (daratumumab-cyclophosphamide-bortezomib-dexamethasone) in the treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.1 The study is not yet recruiting, with an estimated start of January 20271 and plans to enroll 260 participants (estimated).1 Nexcella Inc. is the lead sponsor, with Immix Biopharma, Inc. listed as a collaborator.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.